This case report highlights the link between CD19 downregulation and therapy failure in mantle cell lymphoma, indicating potential challenges for CAR-T treatment.
We report the case of a stage 4 mantle cell lymphoma patient, resistant to conventional first- and second-line therapies, treated with CAR-T cells. The therapy was initially efficacious, with an appreciable CAR-T cells expansion in vivo. However, downregulation of CD19 expression on malignant B cells led to sudden therapy failure.
No takes yet. Share an insight, caveat, or question.
Peruzzi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: